<div id="readability-page-1"><p>TD Cowen analyst Brendan Smith has maintained their bullish  stance on <span>ABSI</span> stock, giving a Buy rating on April 28.</p><div><p>Brendan Smith has given his Buy rating due to a combination of factors related to AbSci’s emerging prolactin receptor franchise and near-term clinical catalysts. He highlights that the newly introduced ABS-202, a second anti-PRLR antibody aimed at an undisclosed immunology indication, broadens the company’s strategic flexibility across multiple disease settings while enhancing pricing and market positioning options.</p><p>  Smith also notes that management sees the PRLR platform as widely applicable, complementing lead asset ABS-201 and enabling AbSci to address different market sizes using its generative AI–powered discovery engine. He underscores that the ongoing Phase 1/2a study for ABS-201 has completed single-ascending-dose cohorts with encouraging tolerability and pharmacokinetics, and that upcoming data readouts in Q2, the second half of 2026, and early 2027 represent meaningful value inflection points that support a favorable risk-reward profile.</p></div><p>In another report released on April 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.</p></div>

ABSI

IBBQ

SBIO

LABU

<p>TD Cowen analyst Brendan Smith has reiterated a Buy rating on AbSci (ABSI) stock, citing the company's emerging prolactin receptor franchise and upcoming clinical catalysts. He emphasizes the strategic flexibility provided by the new ABS-202 antibody and the ongoing Phase 1/2a study for ABS-201, which shows promising results. Smith believes that upcoming data readouts in 2026 and early 2027 will significantly enhance the stock's value. H.C. Wainwright also maintains a Buy rating with an $8.00 price target.</p>

Tip Ranks

Absci

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Brendan Smith Reiterates Buy on AbSci, Citing Emerging PRLR Franchise and Multiple Upcoming Clinical Catalysts